Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection

There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed u...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabie, Al Shaimaa Ibrahim, Salah, Hager, Said, Amira S. A., Shaaban, Ahmed Hassan, Abdou, Lamya Mohamed, Khalil, Doaa Mahmoud, Kharaba, Zelal, Afifi, Hala, Sofy, Mahmoud R., Youssef, Eman M. I., Bayoumy, Eman S. M., Hussein, Raghda R. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957040/
https://www.ncbi.nlm.nih.gov/pubmed/36833140
http://dx.doi.org/10.3390/healthcare11040607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957040/
https://www.ncbi.nlm.nih.gov/pubmed/36833140
http://dx.doi.org/10.3390/healthcare11040607

Ejemplares similares